SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 237 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $242,907 | -99.3% | 9,081 | -99.1% | 0.00% | -99.2% |
| Q1 2024 | $35,206,330 | +32.1% | 1,032,141 | +12.1% | 0.25% | +19.5% |
| Q4 2023 | $26,648,184 | +5.4% | 920,808 | +0.4% | 0.21% | -6.2% |
| Q3 2023 | $25,286,211 | +9.2% | 917,164 | +19.1% | 0.22% | +11.4% |
| Q2 2023 | $23,147,974 | +14.0% | 770,059 | +37.4% | 0.20% | +6.3% |
| Q1 2023 | $20,311,879 | +12.4% | 560,637 | +10.6% | 0.19% | +4.4% |
| Q4 2022 | $18,077,235 | +5.2% | 506,791 | -0.1% | 0.18% | -1.6% |
| Q3 2022 | $17,178,000 | +23.4% | 507,463 | +5.4% | 0.18% | +38.3% |
| Q2 2022 | $13,926,000 | -7.2% | 481,542 | +3.8% | 0.13% | +3.9% |
| Q1 2022 | $15,000,000 | +29.9% | 464,101 | +17.2% | 0.13% | +45.5% |
| Q4 2021 | $11,550,000 | +38.0% | 396,105 | +26.2% | 0.09% | +35.4% |
| Q3 2021 | $8,371,000 | -7.8% | 313,855 | +6.5% | 0.06% | -14.5% |
| Q2 2021 | $9,076,000 | – | 294,781 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthInvest Partners AB | 379,533 | $9,386,000 | 6.98% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 1,022,940 | $25,297,000 | 3.79% |
| ASHFORD CAPITAL MANAGEMENT INC | 642,594 | $15,891,000 | 3.27% |
| Ranger Investment Management | 1,491,835 | $36,893,000 | 2.64% |
| AlphaOne Investment Services, LLC | 210,856 | $5,215,000 | 1.71% |
| NORTHPOINTE CAPITAL LLC | 615,061 | $15,210,000 | 1.58% |
| INSIGHT CAPITAL RESEARCH & MANAGEMENT INC | 141,485 | $3,499,000 | 1.56% |
| FALCON POINT CAPITAL, LLC | 454,002 | $8,989,000 | 1.38% |
| Iguana Healthcare Management, LLC | 300,000 | $7,420,000 | 1.32% |
| KOPP INVESTMENT ADVISORS LLC | 46,839 | $1,158,000 | 1.14% |